Takeda Pharmaceutical of Japan has agreed to purchase biotech firm Shire for $62 billion. The companies had made a preliminary deal for $64 billion in late April, based on a stronger exchange rate for the pound at that time. The acquisition will boost Takeda's product development pipeline in the rare diseases, blood-derived therapies, oncology, gastroenterology and neuroscience sectors.
Takeda to acquire Shire for $62B
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.